Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ashlee Walker

Nurse Practitioner, Family St George, UT Nurse Practitioner

NPI 1770207391 CMS profile 11401721

368 E Riverside Dr Ste A, St George, UT 84790

Open in the dashboard

General payments

$8,407

321 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashlee Walker of St George, UT is reported in the CMS Open Payments database as having received $8,407 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,504 140
2024 General $2,098 96
2023 General $1,489 77
2022 General $316 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashlee Walker
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashlee Walker were reported at $4,504. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashlee Walker Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $316 $141 $44–$430 $149
2023 $1,489 $154 $49–$476 $160
2024 $2,098 $165 $51–$504 $164
2025 $4,504 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Enterra Medical, Inc. $1,667 6 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,446 64 payments
  3. AbbVie, Inc. $1,339 74 payments
  4. Genzyme Corporation $583 29 payments
  5. Janssen Biotech, Inc. $567 18 payments
  6. Ardelyx, Inc. $326 13 payments
  7. Regeneron Healthcare Solutions, Inc. $271 10 payments
  8. Madrigal Pharmaceuticals $233 12 payments
  9. Lilly USA, LLC $227 7 payments
  10. Ipsen Biopharmaceuticals, Inc $176 6 payments
  11. Other $1,571 82 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,419 318 payments
  2. Travel and Lodging $957 2 payments
  3. Education $31 1 payment
Products named General payments · program years 2022–2025
  1. ENTYVIO $1,270 54 payments
  2. RINVOQ $802 45 payments
  3. DUPIXENT Immunology $583 29 payments
  4. SKYRIZI Immunology $510 24 payments
  5. SKYRIZI Immunology $506 26 payments
  6. TREMFYA $497 14 payments
  7. STELARA $375 10 payments
  8. IBSRELA $326 13 payments
  9. LINZESS $210 18 payments
  10. DUPIXENT Immunology And Inflammation $207 7 payments
  11. Other $2,734 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,990

Median for Nurse Practitioner: 389

Drug cost

$1,158,086

Median for Nurse Practitioner: $21,885

Branded share of claims

16.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $557,246
Sucraid Sacrosidase Brand 18 $252,661
Creon Lipase/Protease/Amylase Brand 50 $165,045
Linzess Linaclotide Brand 48 $51,520
Zenpep Lipase/Protease/Amylase Brand 11 $47,959
Motegrity Prucalopride Succinate Brand 15 $9,030
Ursodiol Generic 43 $7,940
Lubiprostone Generic 38 $6,906
Mesalamine Generic 25 $6,631
Pantoprazole Sodium Generic 406 $5,775

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$223,436

Of which drugs: $79,560

Medicare patients

800

Average age 75

Services billed

6,343

484 women, 316 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 55%
Chronic kidney disease 29%
Depression 28%
Ischemic heart disease 26%
Diabetes 24%
Atrial fibrillation 22%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 12 3,900 $62,972

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $372
$372 — 3,900
SKYRIZI
  • AbbVie, Inc. $296
$296 — —
DUPIXENT
  • GENZYME CORPORATION $193
  • Regeneron Healthcare Solutions, Inc. $20
$212 — —
RINVOQ
  • AbbVie, Inc. $198
$198 — —
TREMFYA
  • Janssen Biotech, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record